Galderma 보도자료

2023년 10월 15일 11:11

Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event

Galderma, the emerging pure-play dermatology category leader, today hosts the first edition of its Liquid Live event in Dubai as a chance to discuss with clinicians the future of innovation in the field of neuromodulation as well as showcasing the...

2023년 10월 12일 11:24

Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis

Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis - ARCADIA 1 and 2 and OLYMPIA 1, respectively. The late-breaking data were presented today at the 2023 European Academy of Dermatology ...

2023년 10월 4일 15:05

EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology

Galderma, the emerging pure-play dermatology category leader, announced today it will be showcasing updates from across its broad and innovative dermatology portfolio at the 32nd European Academy of Dermatology and Venereology (EADV) congress in B...

2023년 10월 3일 11:57

Galderma announces progress with RelabotulinumtoxinA regulatory submissions

Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administratio...

2023년 7월 27일 14:16

Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology

Galderma: · Galderma maintained strong momentum across all product categories reaching 2,003 M USD net sales in H1 2023, up 6.9% year-on-year on a constant currency basis · Growth primarily driven by Dermatological Skincare and Therapeutic Dermato...

2023년 7월 4일 17:11

Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4

Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology (WCD) in Singapore. The results highlight the rapid onset of action of nemolizumab monotherapy in patients with prurigo nodular...

2023년 6월 28일 16:22

WCD 2023: Galderma to Present Extensive Data Demonstrating Enduring Commitment to Delivering Innovative Solutions in Dermatology

Galderma will be presenting 59 abstracts/posters from across its extensive portfolio at the 25th World Congress of Dermatology (WCD), reflecting its unrelenting dedication to delivering innovative solutions to advance dermatology for every skin st...

2023년 6월 27일 10:15

Galderma Raises Approximately USD 1 Billion for Newly Issued Shares in a Private Placement Round

Galderma, the emerging pure-play dermatology category leader, announced today a private placement of approximately USD 1 billion for newly issued shares, from a group consisting of current shareholders, new investors, as well as management. The tr...

2023년 4월 19일 14:57

Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables

New global research,[2] sponsored by Galderma and released today by leading filler brand Restylane®, has revealed the prevalent societal misconceptions and stereotypes facing the aesthetics industry. Forty percent of respondents admitted they woul...

2023년 3월 30일 14:35

AMWC 2023: Data From Sculptra® Cheek Wrinkle and Alluzience® Star Studies Reinforce Strength of Galderma’s Broad Aesthetic Portfolio

Galderma will be presenting the latest data from the Sculptra® (injectable poly-L-lactic acid, PLLA-SCA) Cheek Wrinkle and Alluzience® (abobotulinumtoxinA solution) STAR studies at the 21st Aesthetic & Anti-Aging Medical World (AMWC) Congress, tak...

2023년 3월 19일 13:17

AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis

Galderma, the leading company solely dedicated to advancing the future of dermatology, today premiered the positive phase III results from the OLYMPIA 2 trial evaluating the efficacy, safety, pharmacokinetics and immunogenicity of nemolizumab comp...

2023년 3월 13일 15:30

Galderma Delivers Strong FY 2022 Growth Driven by Innovation and Commercial Performance

Galderma: Galderma delivered strong performance · Galderma delivered at the top end of its 2022 revenue guidance with 13.9% year-on-year net sales growth on a constant currency basis at 3,760 M USD and delivered above its 2022 profitability guidan...

2023년 1월 26일 16:26

Galderma Announces the Launch of FACE by Galderma™ - a Game-Changing Augmented Reality Solution Helping Healthcare Professionals Grow Their Activity and Improve Patient Satisfaction

Galderma has announced the launch of FACE by Galderma™, an innovative augmented reality application. The ground-breaking solution enables aesthetic practitioners and patients to visualize treatment results at the planning stage. The technology wil...

2023년 1월 21일 13:20

IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio

Galderma will be showcasing the latest updates from across its portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris from January 26-28, 2023. Events will include several ‘meet the expert’ sessions and ...

2022년 10월 13일 16:30

Galderma Announces Intention to Expand Manufacturing and Innovation Footprint in Asia-Pacific

Reaffirming its bold ambition to become the leading dermatology company in the world, Galderma today announced its intention to expand its manufacturing and innovation footprint in the Asia-Pacific region, with support from the Singapore Economic ...

2022년 9월 20일 17:20

Galderma Debuts The Sensitive Skincare Faculty, a Global Expert Group to Improve Understanding and Management of Sensitive Skin

Reinforcing its commitment to advancing dermatology for every skin story, Galderma announced today the formation of a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives through f...

2022년 9월 6일 16:00

GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress

Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022. These include on-site clinical data presentations, a symposia se...

2022년 8월 25일 15:40

Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio

Galderma: Continued strong commercial and financial performance in a resilient market · Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year on a constant currency basis at 1,914 M USD · Particul...

2022년 6월 22일 16:00

Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis

Galderma today announced the phase III OLYMPIA 2 trial met all primary and key secondary endpoints, showing nemolizumab as monotherapy significantly improved skin lesions and pruritus (itch) compared with placebo in adult patients with moderate to...

2022년 6월 13일 11:25

Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation botulinumtoxinA (RelabotulinumtoxinA) for the Treatment of Glabellar Lines (frown) and Lateral Canthal Lines (crow’s Feet)

Galderma announced today at the Vegas Cosmetic Surgery & Aesthetic Dermatology meeting, topline results from two phase III clinical studies (NCT04249583, NCT04249687) demonstrating that RelabotulinumtoxinA, a novel liquid formulation botulinum tox...

2022년 6월 8일 16:40

Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium

Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will present four scientific presentations at the 2022 Vegas Cosmetic Surgery (VCS) & Aesthetic Dermatology Annual Symposium to showcase the latest...

2022년 6월 2일 11:40

Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022

Galderma will present a range of new clinical data and analyses across its portfolio during nine poster sessions and two symposia at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022...

2022년 3월 29일 11:50

Galderma to Present New Clinical Data and High Patient Satisfaction Across Their Portfolio of Dermal Fillers, Collagen Biostimulators and Liquid Neuromodulators at AMWC 2022

Galderma will present a range of new scientific data on its portfolio on their hyaluronic acid dermal filler range, their first liquid neuromodulator and their original collagen biostimulator at the Aesthetic & Anti-Aging Medicine World Congress (...

2022년 3월 28일 11:45

Galderma to Highlight Latest Science and Innovation Across Its Product Portfolio at the 2022 AAD Annual Meeting

Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy of Dermatology Annual Meeting to showcase its latest approved and investigational product updates. This...

2022년 2월 23일 11:43

Taro to Acquire Alchemee From Galderma

Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Tar...

Galderma

Galderma 보도자료

회사 보도자료 구독